What clinicians should know about the QT interval

被引:461
作者
Al-Khatib, SM [1 ]
LaPointe, NMA [1 ]
Kramer, JM [1 ]
Califf, RM [1 ]
机构
[1] Duke Clin Res Inst, Duke Ctr Educ & Res Therapeut, Durham, NC 27715 USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2003年 / 289卷 / 16期
关键词
D O I
10.1001/jama.289.16.2120
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Of the several factors implicated in causing QT interval prolongation and torsades de pointes, errors in the use of medications that may prolong this interval deserve special attention. Objective To systematically summarize the available clinical data on the QT interval and to offer improved recommendations for the use of QT-prolonging medications. Data Sources We searched MEDLINE from 1966 through 2002 for all English-language articles related to the QT interval. Additional data sources included bibliographies of articles identified on MEDLINE, a survey of experts, and data presented at a meeting of experts on long QT syndrome. Study Selection We selected for review registries and case series examining clinical outcomes of patients,with prolonged QT interval and the effect of different methods of measurement of the QT interval on patient outcomes. Ten studies were identified, of which 6 were included in the analysis. Data Extraction Data quality was determined by publication in the peer-reviewed literature. Data Synthesis Optimal measurement of the QT interval is problematic because of lack of standardization and lack of data regarding the best way to adjust for heart rate. Reliable information on the proper use of QT-prolonging medications is scarce. Although a QT interval of at least 500 milliseconds generally has been shown to correlate with a higher risk of torsades de pointes, there is no established threshold below which prolongation of the QT interval is considered free of proarrhythmic risk. The risk of torsades de pointes should be assessed in patients who are about to begin taking a QT-prolonging medication. Although inadequate clinical studies preclude prediction of absolute risk for individual patients, particularly high-risk situations can be defined based on clinical variables. We propose recommendations on proper monitoring of the QT interval in patients receiving QT-prolonging medications. Conclusion Although the use of QT-prolonging medications can predispose to torsades de pointes, there is a relative paucity of information that can help clinicians and patients make optimal informed decisions about how best to minimize the risk of this serious complication.
引用
收藏
页码:2120 / 2127
页数:8
相关论文
共 55 条
[1]   QT INTERVAL PROLONGATION IN ACUTE MYOCARDIAL-INFARCTION [J].
AHNVE, S .
EUROPEAN HEART JOURNAL, 1985, 6 :85-95
[2]  
Anderson ME, 2001, J PHARMACOL EXP THER, V296, P806
[3]   Cardiac repolarization: Current knowledge, critical gaps, and new approaches to drug development and patient management [J].
Anderson, ME ;
Al-Khatib, SM ;
Roden, DM ;
Califf, RM .
AMERICAN HEART JOURNAL, 2002, 144 (05) :769-781
[4]   Comparison of formulae for heart rate correction of QT interval in exercise electrocardiograms [J].
Aytemir, K ;
Maarouf, N ;
Gallagher, MM ;
Yap, YG ;
Waktare, JEP ;
Malik, M .
PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 1999, 22 (09) :1397-1401
[5]   The QT interval [J].
Bednar, MM ;
Harrigan, EP ;
Anziano, RJ ;
Camm, AJ ;
Ruskin, JN .
PROGRESS IN CARDIOVASCULAR DISEASES, 2001, 43 (05) :1-45
[6]   The Long QT Syndromes: Genetic basis and clinical implications [J].
Chiang, CE ;
Roden, DM .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 36 (01) :1-12
[7]   Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications [J].
Chung, MK ;
Schweikert, RA ;
Wilkoff, BL ;
Niebauer, MJ ;
Pinski, SL ;
Trohman, RG ;
Kidwell, GA ;
Jaeger, FJ ;
Morant, VA ;
Miller, DP ;
Tchou, PJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 32 (01) :169-176
[8]   EFFICACY AND SAFETY OF QUINIDINE THERAPY FOR MAINTENANCE OF SINUS RHYTHM AFTER CARDIOVERSION - A METAANALYSIS OF RANDOMIZED CONTROL TRIALS [J].
COPLEN, SE ;
ANTMAN, EM ;
BERLIN, JA ;
HEWITT, P ;
CHALMERS, TC .
CIRCULATION, 1990, 82 (04) :1106-1116
[9]   Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients [J].
Curtis, LH ;
Ostbye, T ;
Sendersky, V ;
Hutchison, S ;
Lapointe, NMA ;
Al-Khatib, SM ;
Yasuda, SU ;
Dans, PE ;
Wright, A ;
Califf, RM ;
Woosley, RL ;
Schulman, KA .
AMERICAN JOURNAL OF MEDICINE, 2003, 114 (02) :135-141
[10]   Influence of dofetilide on QT-interval duration and dispersion at various heart rates during exercise in humans [J].
Demolis, JL ;
FunckBrentano, C ;
Ropers, J ;
Ghadanfar, M ;
Nichols, DJ ;
Jaillon, P .
CIRCULATION, 1996, 94 (07) :1592-1599